December 29, 2022
Sesen Bio and Carisma Therapeutics Announce Substantial Increase to Expected Special Cash Dividend in Connection with Pending Merger
Sesen Bio and Carisma Therapeutics Announce Substantial Increase to Expected Special Cash Dividend in Connection with Pending Merger
Sesen Bio Stockholders Expected to Receive ...
Read more
Read more
December 22, 2022
Targovax announces that the TG01 study in multiple myeloma at Oslo University Hospital has received regulatory approvals to proceed
The Norwegian Medicines Agency (NOMA) and the Regional Ethics Committee (REK) have today approved the clinical trial application for TG01 in multiple myeloma
The Norwegia...
Read more
Read more
December 20, 2022
HelloBetter Sleep: First online therapy programme for organic and nonorganic insomnia available on prescription in Germany
Berlin, 20.12.2022 – HelloBetter Sleep has secured approval as HelloBetter’s sixth DiGA (prescription digital therapeutic) by the German Federal Institute for Drugs ...
Read more
Read more
December 15, 2022
Marston Forest Healthcare live with Doctrin – the next generation care navigation and online consultation platform
Press release - 15 December 2022
Marston Forest Healthcare, a 10,000 patient GP practice in Berkshire have gone live with the Doctrin platform - a next generation care navigati...
Read more
Read more
December 15, 2022
Targovax announces clinical trial collaboration with Agenus to test TG mutant RAS vaccination in pancreatic cancer
The trial will be sponsored by The University of Kansas Cancer Center and led by Dr. Anup Kasi, a leading expert in gastrointestinal cancersCollaboration partner Agenus will provi...
Read more
Read more
December 14, 2022
American Lung Association Campaign Shines Spotlight on Endobronchial Valves for Advanced COPD/Emphysema
Pulmonx Highlights 2022 Partnership with Lung Association
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Dec. 14, 2022-- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonxâ€...
Read more
Read more
December 12, 2022
Oncopeptides presents new scientific data at the Annual American Society of Hematology Meeting ASH
STOCKHOLM — December 12, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat ...
Read more
Read more
December 8, 2022
Vicore has carried out a directed share issue of 10,000,000 shares at a subscription price of SEK 20 per share, raising gross proceeds of SEK 200 million
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN OR ANY OTH...
Read more
Read more
December 7, 2022
Oncopeptides provides update on Pepaxto US marketing authorization
STOCKHOLM — December 07, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hemato...
Read more
Read more
December 5, 2022
Vicore announces first patient enrolled in COMPANION; a digital therapeutic pivotal study for patients with pulmonary fibrosis
First randomized clinical investigation with a digital therapy (DTx) to address the psychological symptom burden in pulmonary fibrosis (PF) patientsFirst patient enrolled in US pi...
Read more
Read more